Kristin Tissera

Ms. Kristin Tissera

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Children
Verified
Journal Article
Open access
PDF file
MMMia Mologousis
Mia Mologousis
STSerena Yun-Chen Tsai
Serena Yun-Chen Tsai
KTKristin Tissera
Kristin Tissera
YLYakir S. Levin
Yakir S. Levin
Elena B. HawrylukElena B. Hawryluk
Elena B. Hawryluk
Congenital melanocytic nevi (CMN) carry an increased risk of melanoma and may be disfiguring, and consensus regarding treatment recommendations is lacking. While clinical monitoring is the standard of care, many caregivers are interested in its removal to prevent psychosocial burden or to decrease risk. Although melanoma can occur regardless of CMN removal, there are a variety of treatments that may offer improved cosmesis or local symptom control, including surgical excision, laser therapy, and other superficially destructive techniques. Regardless of the selected management, these patients are monitored for ongoing melanoma risk. An extensive discussion with families regarding the risks and benefits of observation versus active intervention is essential. To facilitate these discussions, we herein summarize current CMN management strategies and considerations.

4 November 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
KBK. Bouhadjer
K. Bouhadjer
KTKristin Tissera
Kristin Tissera
CFC.W. Farris
C.W. Farris
AJA.F Juliano
A.F Juliano
MCM.E. Cunnane
M.E. Cunnane
KRK.L. Reinshagen
K.L. Reinshagen
Objective To compare the prevalence of sexually transmitted infections (STIs) (including HIV) and of high-risk sexual behaviour in the following three groups: primary infertile relationships, secondary infertile relationships and fertile relationships. Primary infertility is here defined as never having conceived before, secondary infertility as infertility subsequent to having conceived at least once. Design Unmatched case–control study. Methods Sexually active infertile women aged 21–45 years presenting at an infertility clinic of the Kigali Teaching Hospital, Rwanda and their male partners were invited to participate. Fertile controls who had recently delivered were recruited from the community. In a face-to-face interview, participants were asked about sociodemographic characteristics and their sexual behaviours, and tested for HIV and STIs. Results Between November 2007 and May 2009, 312 women and 254 partners in infertile relationships and 312 women and 189 partners in fertile relationships were enrolled. Involvement in a secondary infertile relationship was associated with HIV infection after adjusting for sociodemographic covariates for women (adjusted OR (AOR)=4.03, 95% CI 2.4 to 6.7) and for men (AOR=3.3, 95% CI 1.8 to 6.4). Involvement in a primary infertile relationship, however, was not. Secondary infertile women were more likely to have engaged in risky sexual behaviour during their lifetime compared with primary infertile and fertile women. Men in primary and secondary infertile relationships more often reported multiple partners in the past year (AOR=5.4, 95% CI 2.2 to 12.7; AOR=7.1, 95% CI 3.2 to 15.8, respectively). Conclusions Increased HIV prevalence and risky sexual behaviour among infertile couples is driven by secondary infertility. Infertile couples, and especially those with secondary infertility, should be targeted for HIV prevention programmes and their fertility problems should be addressed.

21 January 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
AWAlisha Williams
Alisha Williams
WGWilliam Goedicke
William Goedicke
KTKristin Tissera
Kristin Tissera
LMLeila A. Mankarious
Leila A. Mankarious

14 April 2020 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
PDF file
AWAlisha Williams
Alisha Williams
MPMargaret Pulsifer
Margaret Pulsifer
KTKristin Tissera
Kristin Tissera
LMLeila A. Mankarious
Leila A. Mankarious

28 June 2024 in Pediatric Dermatology
Verified
Journal Article
Closed access
KTKristin Tissera
Kristin Tissera
KGKristina Gorbatenko‐Roth
Kristina Gorbatenko‐Roth
NPNeil S. Prose
Neil S. Prose
KJKirsten Johnson
Kirsten Johnson

2 September 2025 in JID Innovations
Verified
Journal Article
Open access
CBChristian L. Bailey-Burke
Christian L. Bailey-Burke
KTKristin Tissera
Kristin Tissera
LBLauren Baughman
Lauren Baughman
SPSamantha A. Polly
Samantha A. Polly
MKMeenal Kheterpal
Meenal Kheterpal
The management of dermatologic immune–related adverse events (D-irAEs) remains inconsistent owing to variability in treatment responses and a lack of standardized guidelines. Establishing evidence-based recommendations is critical to improving patient outcomes and minimizing interruptions in immune checkpoint inhibitor therapy. This review aims to systematically evaluate the level of evidence for reported D-irAE treatments and provide insights to guide clinical decision making. Of the D-irAEs identified, those that were commonly reported include maculopapular, lichenoid, psoriasiform, immunobullous (including bullous pemphigoid), granulomatous, vitiligo, and potentially life-threatening erosive mucocutaneous conditions (such as erythema multiforme, Steven–Johnson syndrome, and toxic epidermal necrosis). Treatments ranged from corticosteroids (topical, oral, intravenous) to biologics (eg, omalizumab, rituximab) and oral immunomodulators (eg, methotrexate, apremilast), with topical and oral corticosteroids, along with apremilast, receiving the strongest evidence rating (3B). Although the strongest evidence supports corticosteroids, most treatments for D-irAEs lack robust validation owing to limitations in study type (ie, randomized control trials and prospective cohort studies). This underscores the importance of multidisciplinary approaches to optimize D-irAE management and support continuity in cancer care. Future research should prioritize randomized control trials and prospective cohort studies to aid in standardizing D-irAE treatment protocols to solidify treatment consensus.